Vicore Pharma Holding AB (OSTO:VICO) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Vicore Pharma Holding AB Days Payable?

Vicore Pharma Holding AB's average Accounts Payable for the three months ended in Dec. 2024 was kr21.2 Mil. Vicore Pharma Holding AB's Cost of Goods Sold for the three months ended in Dec. 2024 was kr0.0 Mil.

The historical rank and industry rank for Vicore Pharma Holding AB's Days Payable or its related term are showing as below:

OSTO:VICO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 118.34
* Ranked among companies with meaningful Days Payable only.

Vicore Pharma Holding AB's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Vicore Pharma Holding AB Days Payable Historical Data

The historical data trend for Vicore Pharma Holding AB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Days Payable Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

Vicore Pharma Holding AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Vicore Pharma Holding AB's Days Payable

For the Biotechnology subindustry, Vicore Pharma Holding AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Days Payable distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Days Payable falls into.

Save Embed

;

Save Embed

;

Vicore Pharma Holding AB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Vicore Pharma Holding AB's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (17.916	+	29.966)	/	2 )	/	0	*	365
=	23.941					/	0	*	365
=	N/A

Vicore Pharma Holding AB's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (12.433	+	29.966)	/	2 )	/	0	*	365 / 4
=	21.1995					/	0	*	365 / 4
=	N/A

Vicore Pharma Holding AB Days Payable Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

6Y4:Germany

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines